TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON — Jean-François H. Geschwind (2016) | RDL Network
Global variation exists in TACE use in sorafenib-treated HCC patients. The combination of TACE with sorafenib appears to be a well-tolerated and viable therapeutic approach.
Marta Burrel, María Reig, Alejandro Forner, Marta Barrufet, Carlos Rodríguez de Lope, Silvia Tremosini, Carmen Ayuso, Josep M. Llovet, María Isabel Real, Jordi Bruix
Markus Peck‐Radosavljevic, Masatoshi Kudo, Jean‐Luc Raoul, Han Chu Lee, Thomas Decaens, Jeong Heo, Shi‐Ming Lin, Hong Shan, Yefa Yang, Inga Bayh, Keiko Nakajima, Ann‐Lii Cheng
Discussion(0)
No comments yet. Be the first to comment.